id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-P-3482-0003,FDA,FDA-2024-P-3482,"Determination That JESDUVROQ (daprodustat) Tablets, 1 Milligram, 2 Milligrams, 4 Milligrams, 6 Milligrams, and 8 Milligrams, Were Not Withdrawn
From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2024-11-19T05:00:00Z,2024,11,2024-11-19T05:00:00Z,,2024-11-19T15:23:17Z,2024-26915,0,0,090000648682768f
FDA-2024-P-3482-0004,FDA,FDA-2024-P-3482,"Final Response Letter from FDA CDER to Qilu Pharmaceutical (Hainan) Co., Ltd",Other,Denial of Petition,2024-11-19T05:00:00Z,2024,11,2024-11-19T05:00:00Z,,2024-11-19T20:39:48Z,,0,0,0900006486829107
FDA-2024-P-3482-0002,FDA,FDA-2024-P-3482,"Acknowledgment Letter from FDA DMS to Qilu Pharmaceutical (Hainan) Co., Ltd.",Other,Acknowledgement Letter/Receipt,2024-07-25T04:00:00Z,2024,7,2024-07-25T04:00:00Z,,2024-07-25T20:03:01Z,,0,0,09000064866054de
FDA-2024-P-3482-0001,FDA,FDA-2024-P-3482,"Citizen Petition from Qilu Pharmaceutical (Hainan) Co., Ltd.",Other,Citizen Petition,2024-07-25T04:00:00Z,2024,7,2024-07-25T04:00:00Z,,2024-11-19T19:31:25Z,,0,0,09000064866054dd